ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 171 • 2015 ACR/ARHP Annual Meeting

    Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients

    Jana Hurnakova1, Jakub Zavada1, Petra Hanova1, Hana Hulejová1, Martin Klein1, Herman F Mann1, Olga Sleglova1, Marta Olejarova1, Šárka Forejtová1, Olga Ruzickova1, Martin Komarc2, Jiri Vencovsky1, Karel Pavelka1 and Ladislav Senolt1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small…
  • Abstract Number: 583 • 2015 ACR/ARHP Annual Meeting

    A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year

    Anne Sofie Siebuhr1, Stephanie Nina Kehlet2, Kishwar Musa2, Inger Byrjalsen3, Morten Asser Karsdal4 and Anne C. Bay-Jensen5, 1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Laboratory, Nordic Bioscience, Herlev, Denmark, 3Research & Development, Nordic Bioscience, Herlev, Denmark, 4Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 5Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Protease activity, especially MMP3, is known to be increased with arthritis, such as rheumatoid arthritis. MMP3 is mainly expressed by fibroblasts; a key cell…
  • Abstract Number: 1023 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma

    Kathryn S. Torok1, Jonathan Yabes2, Qi Mi3, Christina Kelsey1 and Kelsey Magee4, 1Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, 4Pediatrics, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose:   Localized scleroderma has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue.   The extent and duration of…
  • Abstract Number: 1579 • 2015 ACR/ARHP Annual Meeting

    Association of Myocardial Abnormalities with N-Terminal Pro-Brain Natriuretic Peptide and Disease Activity in Rheumatoid Arthritis without Cardiac Symptoms, Assessed By Cardiac Magnetic Resonance Imaging

    Hitomi Kobayashi1, Yasuyuki Kobayashi2, Isamu Yokoe3, Natsumi Ikumi4,5, Hirotake Inomata6, Atsuma Nishiwaki6, Noboru Kitamura1, Kaita Sugiyama6, Hidetake Shiraiwa6, Masataka Nozaki6, Yosuke Nagasawa6, Yoshihiro Matsukawa5 and Masami Takei1, 1Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, 3Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 4Nihon University School of Medicine, Shinjuku, Japan, 5Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 6Nihon University School of Medicine, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a multi-organ inflammatory disorder associated with high cardiovascular morbidity and mortality. Cardiac involvements are typically clinically silent, only manifesting as…
  • Abstract Number: 1936 • 2015 ACR/ARHP Annual Meeting

    STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study

    Arthur G Pratt1, Amy E. Anderson1, Dennis W Lendrem2, Andrew Skelton2, Jonathan Massey3, Nisha Nair3, Julie Diboll2, Ben Hargreaves2, Philip M Brown2, Anne Barton4,5 and John D Isaacs2, 1Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 3NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom

    Background/Purpose:  A previously described transcriptional signature present in circulating CD4+ T cells of early rheumatoid arthritis (RA) patients implicated STAT3 signalling as an early pathophysiological…
  • Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting

    Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy

    Femke Lamers-Karnebeek1, Marjan Ghiti Moghadam2, Harald E. Vonkeman3, Janneke Tekstra4, Annemarie Schilder5, Henk Visser6, Peter M. ten Klooster7, Eric H. Sasso8, David Chernoff9, Willem Lems10, Dirkjan van Schaardenburg11, Robert Landewé12, Iet Van Albada13, T.R.D.J. Radstake14, Piet van Riel15, Mart A.F.J. van de Laar16 and Tim Jansen17, 1Rheumatology, Radboudumc, Nijmegen, Netherlands, 2rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 3Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 4Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, 6Rheumatology, Alysis Care Group, Arnhem, Netherlands, 7Pcgr, University of Twente, Enschede, Netherlands, 8Crescendo Bioscience Inc., South San Francisco, CA, 9Crescendo Bioscience, Inc., South San Francisco, CA, 10Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Department of Rheumatology, Amsterdam, Netherlands, 11Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, 12Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, 13Meander MC, Amersfoort, Netherlands, 14Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 15Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 16Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, 17VieCuri Medical Center, Venlo, Netherlands

    Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…
  • Abstract Number: 2984 • 2015 ACR/ARHP Annual Meeting

    Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity:  Correlation with Pulmonary Function

    Merrideth Ashley Morris1, Tanjina Akter2, Paul Nietert3, Galina S. Bogatkevich2 and Richard Silver4, 1Medical University of South Carolina, Charleston, SC, 2Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 3Division of Public Health Science, Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Multiple lines of evidence identify thrombin as an important mediator of lung fibrosis in systemic sclerosis (SSc).  In addition to demonstrating dramatically high levels…
  • Abstract Number: 189 • 2015 ACR/ARHP Annual Meeting

    Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers

    Shin-ya Kawashiri1,2, Ayako Nishino3, Masataka Umeda3, Shoichi Fukui1, Yoshikazu Nakashima3, Naoki Iwamoto1, Kunihiro Ichinose1, Hideki Nakamura1, Tomoki Origuchi4, Kiyoshi Aoyagi2 and Atsushi Kawakami3, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 4Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Methods: Twenty-five active RA patients (mean disease durations 7.5 years and DAS28-ESR 5.90) who fulfilled 2010 RA classification criteria were consecutively enrolled in this study.…
  • Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting

    Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab

    Ignacio Ortea1, Bernd Roschitzki2, Eva Tomero3, Juan G. Ovalles-Bonilla4, Javier Lopez-Longo5, Inmaculada de la Torre5, Isidoro Gonzalez-Alvaro6, Juan J Gomez-Reino7 and Antonio Gonzalez8, 1Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, 2Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, 3Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 5Gregorio Marañon Hospital, Madrid, Spain, 6Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, 7Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 8Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain

    Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
  • Abstract Number: 1051 • 2015 ACR/ARHP Annual Meeting

    Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome

    Gabriela Moreira Balarini1, Eliana Zandonade2, leandro tanure3, gilda Aparecida ferreira3, Wildner Mardegan Sardenberg4, Érica Vieira Serrano4, Cléia Coelho Dias5, Túlio Pinho Navarro3, João Felipe Tonini4, Hilde H Nordal6, Piotr Mydel7, Johan Gorgas Brun8, Karl Albert Brokstad9, Eva Gerdts8, Roland Jonsson10,11 and Valeria Valim4,12, 1Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., cachoeiro de itapemirim, Brazil, 2Department of Statistic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, 3Department of Locomotor System, Federal University of Minas Gerais, Brazil., belo horizonte, Brazil, 4Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, 5Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vila velha, Brazil, 6Broegelmann Research Laboratory/University of Bergen, Norway, bergen, Norway, 7Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, 8Department of Clinical Science, University of Bergen, Norway, bergen, Norway, 9Department of Clinical Science, University of Bergen, Norway., bergen, Norway, 10Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 11Broegelmann research laboratory, Bergen, Norway, 12Rheumatology, Universidade Federal do Espírito Santo, Vitória, Brazil

    Background/Purpose: The relationship between atherosclerosis, traditional risk factors, disease activity and biomarkers is not well explored. We aimed to identify the association of carotid atherosclerosis…
  • Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting

    Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment

    Matthieu Lavielle1, Denis Mulleman1, Hsueh Cheng Sung2, Clément Bahuaud2, Philippe Goupille1, Hervé Watier3 and Gilles Thibault3, 1Service de Rhumatologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France, 2Université François-Rabelais de Tours, CNRS 7292, Tours, France, 3Laboratoire d'Immunologie, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, Tours, France

    Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…
  • Abstract Number: 1937 • 2015 ACR/ARHP Annual Meeting

    Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis

    Ernesto J. Munoz-Elias1, David Peckham1, Kayla Norton1, Judilyn Duculan2, Inna Cueto2, Xuan Li3, James Qin4, Kurt Lustig5, Eric Tarcha1, Jared Odegard4, James G. Krueger2 and Shawn P. Iadonato1, 1Kineta Inc, Seattle, WA, 2Rockefeller University, New York, NY, 3Rockefeller University, New York, WA, 4Benaroya Research Institute at Virginia Mason, Seattle, WA, 5Kineta Inc., Seattle, WA

    Background/Purpose: Effector memory T cells of both CD4 and CD8 lineages are key drivers of autoimmunity and are pathogenic in several autoimmune diseases including psoriasis,…
  • Abstract Number: 2601 • 2015 ACR/ARHP Annual Meeting

    The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression

    Chantal A.M. Bouman1, Aatke van der Maas1, Noortje van Herwaarden1, Eric H. Sasso2, Frank H.J. van den Hoogen1 and Alfons A. den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: We evaluated the predictive value of the multi-biomarker disease activity (MBDA) score for clinical outcomes and radiographic progression in a TNFi tapering study in…
  • Abstract Number: 2990 • 2015 ACR/ARHP Annual Meeting

    Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort

    Anna-Maria Hoffmann-Vold1,2, Oyvind Midtvedt1, Torhild Garen3, May Brit Lund4, Arne Andreassen5 and Øyvind Molberg6, 1Rheumatology, Oslo University Hospital, Oslo, Norway, 2Institute of clinical medicine, University of Oslo, Oslo, Norway, 3Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Respiratory Diseases, Oslo University Hospital, Oslo, Norway, 5Cardiology, Oslo University Hospital, Oslo, Norway, 6Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway

    Background/Purpose: In Systemic Sclerosis (SSc), pulmonary arterial hypertension (PAH) is often diagnosed at an advanced stage. Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are…
  • Abstract Number: 217 • 2015 ACR/ARHP Annual Meeting

    Circulating Levels of Neo-Epitopes Reflecting Connective Tissue Turnover As Biomarkers of Gout and Frequent Gout Attacks in Men

    Ana Valdes1, Tina Manon-Jensen2, Wendy Jenkins3, Anne Sofie Siebuhr4, Morten Asser Karsdal4, Sally Doherty5, Abhishek Abhishek3, Helen Richardson3, Weiya Zhang6, Michael Doherty7 and Anne C. Bay-Jensen8, 1Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, United Kingdom, 2Antibody Research Unit, Nordic Bioscience, 2370, Denmark, 3Devision of Rheumatology, University of Nottingham, NG5 1PB, England, 4Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 5Division of ROD, University of Nottingham, Nottingham, United Kingdom, 6Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, 7Academic Rheumatology, City Hospital, Nottingham, United Kingdom, 8Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Recurrent flares constitute the main clinical burden of gout. The neo-epitope blood-based biomarkers, C1M and C3M, measuring matrix metalloproteinases (MMP)-mediated connective tissue degradation, have previously…
  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology